Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 16.47% is 28% below its 5-year average of 22.74%, around the middle of its 5-year range (8.00%–31.56%).
As of the fiscal period ended Tuesday, June 30, 2026. 19.12% above its 12-month average of 13.83%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 16.47%.
DEBT TO ASSETS RATIO
16.47%
DEBT TO ASSETS RATIO AVG TTM
13.83%
DEBT TO ASSETS RATIO AVG 3Y
18.70%
DEBT TO ASSETS RATIO AVG 5Y
22.74%
DEBT TO ASSETS RATIO AVG 10Y
23.64%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+19.12%
CURRENT VS 3Y AVG
-11.92%
CURRENT VS 5Y AVG
-27.55%
CURRENT VS 10Y AVG
-30.32%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 706 covered companies
CURRENT VS SECTOR MEDIAN
+16372.05%
vs the sector median at left
Organogenesis Holdings Inc.
Market Cap
$169.40M
Debt to Assets Ratio
16.47%
TTM Avg
13.83%
3Y Avg
18.70%
5Y Avg
22.74%
Market Cap
$173.23M
Debt to Assets Ratio
0.10%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$165.34M
Debt to Assets Ratio
0.10%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$164.54M
Debt to Assets Ratio
0.20%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$174.56M
Debt to Assets Ratio
0.29%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$175.13M
Debt to Assets Ratio
0.22%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Organogenesis Holdings Inc. (ORGO) | $169.40M | 16.47% | 13.83% | 18.70% | 22.74% |
| OptimizeRx Corp. (OPRX)vs › | $166.82M | 0.12% | N/A | N/A | N/A |
| Nkarta, Inc. (NKTX)vs › | $172.78M | 0.22% | N/A | N/A | N/A |
| MediWound Ltd. (MDWD)vs › | $172.97M | 0.13% | N/A | N/A | N/A |
| ProQR Therapeutics N.V. (PRQR)vs › | $173.23M | 0.10% | N/A | N/A | N/A |
| Quanterix Corporation (QTRX)vs › | $165.34M | 0.10% | N/A | N/A | N/A |
| Coherus Oncology, Inc. (CHRS)vs › | $164.54M | 0.20% | N/A | N/A | N/A |
| Cue Biopharma, Inc. (CUE)vs › | $174.56M | 0.29% | N/A | N/A | N/A |
| Precision BioSciences, Inc. (DTIL)vs › | $175.13M | 0.22% | N/A | N/A | N/A |
| PepGen Inc. (PEPG)vs › | $163.59M | 0.11% | N/A | N/A | N/A |
Debt/Assets
16.5%
Debt/Equity
0.23
Current Ratio
3.52
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 16.47% |
| 2026-03-31 | 13.63% |
| 2025-12-31 | 22.19% |
| 2025-09-30 | 8.00% |
| 2025-06-30 | 8.85% |
| 2025-03-31 | 9.12% |
| 2024-12-31 | 8.70% |
| 2024-09-30 | 24.12% |
| 2024-06-30 | 25.47% |
| 2024-03-31 | 25.88% |
| 2023-12-31 | 25.94% |
| 2023-09-30 | 27.02% |
| 2023-06-30 | 27.70% |
| 2023-03-31 | 27.87% |
| 2022-12-31 | 27.55% |
| 2022-09-30 | 28.59% |
| 2022-06-30 | 28.84% |
| 2022-03-31 | 29.84% |
| 2021-12-31 | 29.85% |
| 2021-09-30 | 30.26% |
| 2021-06-30 | 31.56% |
| 2021-03-31 | 31.07% |
| 2020-12-31 | 29.21% |
| 2020-09-30 | 46.56% |
| 2020-06-30 | 53.27% |
| 2020-03-31 | 52.80% |
| 2019-12-31 | 45.59% |
| 2019-09-30 | 57.75% |
| 2019-06-30 | 53.69% |
| 2019-03-31 | 49.91% |
| 2018-12-31 | 36.21% |
| 2018-09-30 | 0.22% |
| 2018-06-30 | 0.15% |
| 2018-03-31 | 0.10% |
| 2017-12-31 | 5.71% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.10% |
| 2016-06-30 | 29.49% |
